BeiGene (BGNE) News Today → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free BGNE Stock Alerts $153.58 +5.02 (+3.38%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineHillhouse Boosts Longi Position After Robe, As It Pivots To Global Focusbenzinga.com - April 26 at 7:19 PMBeiGene, Ltd.: BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Reportfinanznachrichten.de - April 26 at 2:19 PMBeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Reportbusinesswire.com - April 26 at 10:34 AMHandelsbanken Fonder AB Sells 6,529 Shares of BeiGene, Ltd. (NASDAQ:BGNE)marketbeat.com - April 26 at 6:39 AMBeiGene (NASDAQ:BGNE) PT Raised to $236.00 at TD Cowenamericanbankingnews.com - April 26 at 3:44 AMBeiGene (NASDAQ:BGNE) Trading Up 4.3% After Analyst Upgradeamericanbankingnews.com - April 26 at 2:02 AMBeiGene (NASDAQ:BGNE) Trading 4.3% Higher After Analyst Upgrademarketbeat.com - April 25 at 12:07 PMBeiGene (NASDAQ:BGNE) Shares Gap Up to $130.94americanbankingnews.com - April 25 at 5:44 AMEvaluating BeiGene: Insights From 6 Financial Analystsmarkets.businessinsider.com - April 24 at 4:52 PMGlobal Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meetingbusinesswire.com - April 24 at 4:01 PMBeiGene (NASDAQ:BGNE) Given New $236.00 Price Target at TD Cowenmarketbeat.com - April 24 at 1:57 PMEU regulators approve BeiGene's tislelizumab for lung cancermsn.com - April 23 at 3:33 PMWith 42% ownership of the shares, BeiGene, Ltd. (NASDAQ:BGNE) is heavily dominated by institutional ownersfinance.yahoo.com - April 23 at 10:32 AMBeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancerbusinesswire.com - April 23 at 6:00 AMBeiGene (NASDAQ:BGNE) Trading Down 2.4%americanbankingnews.com - April 21 at 3:12 AMBeiGene (NASDAQ:BGNE) Shares Down 2.4% marketbeat.com - April 19 at 12:24 PMBeiGene, Ltd. (NASDAQ:BGNE) Receives Average Recommendation of "Moderate Buy" from Analystsamericanbankingnews.com - April 19 at 2:18 AMBeiGene (NASDAQ:BGNE) Sets New 12-Month Low at $131.50marketbeat.com - April 17 at 12:20 PMBeiGene Becomes Oversold (BGNE)nasdaq.com - April 14 at 1:21 PMBeiGene, Ltd. (NASDAQ:BGNE) Shares Sold by DekaBank Deutsche Girozentralemarketbeat.com - April 14 at 5:10 AMBeiGene CEO John Oyler sells shares worth over $7.4 millioninvesting.com - April 13 at 10:25 AMInsider Selling: BeiGene, Ltd. (NASDAQ:BGNE) CEO Sells 26,716 Shares of Stockinsidertrades.com - April 12 at 6:27 AMBeiGene, Ltd. (NASDAQ:BGNE) CEO Sells $3,977,745.24 in Stockmarketbeat.com - April 11 at 6:34 PMBeiGene (NASDAQ:BGNE) Shares Gap Up to $149.75marketbeat.com - April 9 at 11:25 AMBeiGene (NASDAQ:BGNE) Price Target Cut to $164.30 by Analysts at Bank of Americamarketbeat.com - April 8 at 1:29 PMBeiGene, Ltd. (NASDAQ:BGNE) Short Interest Updatemarketbeat.com - March 31 at 9:32 PM4 Analysts Assess BeiGene: What You Need To Knowmarkets.businessinsider.com - March 27 at 1:36 PMShareholders in BeiGene (NASDAQ:BGNE) have lost 54%, as stock drops 8.5% this past weekfinance.yahoo.com - March 27 at 1:36 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and BeiGene (BGNE)markets.businessinsider.com - March 27 at 8:36 AMSanford C. Bernstein Trims BeiGene (NASDAQ:BGNE) Target Price to $161.00marketbeat.com - March 27 at 8:18 AMBeiGene, Ltd. (NASDAQ:BGNE) Shares Sold by Matthews International Capital Management LLCmarketbeat.com - March 25 at 4:23 PMWellington Management Group LLP Buys 20,239 Shares of BeiGene, Ltd. (NASDAQ:BGNE)marketbeat.com - March 25 at 4:09 AMBeiGene appoints new principal accounting officerinvesting.com - March 22 at 7:33 PMBeiGene (NASDAQ:BGNE) Price Target Raised to $186.00 at JPMorgan Chase & Co.marketbeat.com - March 20 at 10:39 AMBeiGene, Ltd. (NASDAQ:BGNE) Short Interest Up 10.3% in Februarymarketbeat.com - March 19 at 7:35 AMBGNE Apr 2024 140.000 putfinance.yahoo.com - March 16 at 2:09 PMBGNE Apr 2024 220.000 callfinance.yahoo.com - March 16 at 9:08 AMBGNE Apr 2024 125.000 putfinance.yahoo.com - March 16 at 9:08 AMBGNE Apr 2024 180.000 callca.finance.yahoo.com - March 16 at 1:15 AMBGNE Apr 2024 135.000 putca.finance.yahoo.com - March 16 at 1:15 AMBeiGene, Ltd. (NASDAQ:BGNE) CEO John Oyler Sells 37,668 Sharesinsidertrades.com - March 15 at 10:54 AMBeiGene, Ltd. (NASDAQ:BGNE) CEO Sells $6,178,305.36 in Stockmarketbeat.com - March 14 at 7:24 PMBeiGene gets FDA approval for esophageal cancer drug Tevimbramsn.com - March 14 at 7:08 PMBeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapyfinance.yahoo.com - March 14 at 7:07 PMBeiGene (NASDAQ:BGNE) Shares Gap Up to $163.75marketbeat.com - March 13 at 12:32 PMFDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancermsn.com - March 8 at 3:51 PMBeiGene Still Bleeding Red Ink Despite Blockbuster Drugseekingalpha.com - March 8 at 5:10 AMBeiGene gets FDA accelerated approval for Brukinsa for follicular lymphomamsn.com - March 7 at 7:11 PMBeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphomabusinesswire.com - March 7 at 5:19 PMUS FDA approves expanded use of BeiGene's blood cancer drugreuters.com - March 7 at 3:50 PM Get BeiGene News Delivered to You Automatically Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy BGNE Media Mentions By Week BGNE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BGNE News Sentiment▼0.380.32▲Average Medical News Sentiment BGNE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BGNE Articles This Week▼174▲BGNE Articles Average Week Get BeiGene News Delivered to You Automatically Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KRTX News Today VTRS News Today RDY News Today SRPT News Today TEVA News Today UTHR News Today CTLT News Today LEGN News Today BMRN News Today ASND News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BGNE) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryWhy Big Pharma is Investing Billions in This BiotechBehind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeiGene, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
